Simon R Best1, Michael Mohr2, Karen B Zur3,4. 1. Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, Maryland, U.S.A. 2. Department of Medicine, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany. 3. Pediatric Otolaryngology, The Children's Hospital of Philadelphia, The University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A. 4. Department of Otolaryngology-Head and Neck Surgery, The University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: Aggressive laryngeal, tracheal, and pulmonary papilloma is an extremely challenging clinical problem without proven treatment options. A recent German report documented promising results with systemic bevacizumab. The objective of this study is to report the initial experience of this novel treatment in the United States for recurrent respiratory papillomatosis (RRP). STUDY DESIGN: Cases series. METHODS: Electronic survey of the RRP Task Force of the American Society of Pediatric Otolaryngology, American Broncho-Esophagological Association, and physicians known to the authors to have used systemic bevacizumab for RRP. RESULTS: Eleven completed surveys were obtained. In three cases, systemic bevacizumab was considered clinically but not administered. Eight patients were treated with systemic bevacizumab, all for aggressive papillomatosis uncontrolled by surgical and adjuvant therapy, including seven of eight with pulmonary disease. Treatment dosing ranged from 5 to 10 mg/kg every 2 to 4 weeks, with all patients responding (7/8 partial response, 1/8 complete response). In four patients who had postbevacizumab chest imaging, three demonstrated improvement of disease and one stabilization. Treatment interval could be lengthened in seven patients and clinical response maintained. One patient with long-standing pulmonary disease (>10 years) was diagnosed with malignant transformation while on treatment, and bevacizumab was discontinued in lieu of other chemotherapeutic agents. All other patients continue on systemic bevacizumab with minimal complications (hemoptysis n = 1, proteinuria n = 1). CONCLUSIONS: Systemic bevacizumab appears to have significant promise in the most treatment-resistant and aggressive forms of papillomatosis with a low complication profile. These results suggest bevacizumab should be studied in a formal clinical trial for RRP. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:2225-2229, 2017.
OBJECTIVES/HYPOTHESIS: Aggressive laryngeal, tracheal, and pulmonary papilloma is an extremely challenging clinical problem without proven treatment options. A recent German report documented promising results with systemic bevacizumab. The objective of this study is to report the initial experience of this novel treatment in the United States for recurrent respiratory papillomatosis (RRP). STUDY DESIGN: Cases series. METHODS: Electronic survey of the RRP Task Force of the American Society of Pediatric Otolaryngology, American Broncho-Esophagological Association, and physicians known to the authors to have used systemic bevacizumab for RRP. RESULTS: Eleven completed surveys were obtained. In three cases, systemic bevacizumab was considered clinically but not administered. Eight patients were treated with systemic bevacizumab, all for aggressive papillomatosis uncontrolled by surgical and adjuvant therapy, including seven of eight with pulmonary disease. Treatment dosing ranged from 5 to 10 mg/kg every 2 to 4 weeks, with all patients responding (7/8 partial response, 1/8 complete response). In four patients who had postbevacizumab chest imaging, three demonstrated improvement of disease and one stabilization. Treatment interval could be lengthened in seven patients and clinical response maintained. One patient with long-standing pulmonary disease (>10 years) was diagnosed with malignant transformation while on treatment, and bevacizumab was discontinued in lieu of other chemotherapeutic agents. All other patients continue on systemic bevacizumab with minimal complications (hemoptysis n = 1, proteinuria n = 1). CONCLUSIONS: Systemic bevacizumab appears to have significant promise in the most treatment-resistant and aggressive forms of papillomatosis with a low complication profile. These results suggest bevacizumab should be studied in a formal clinical trial for RRP. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:2225-2229, 2017.
Authors: Valentin Gerein; Eugen Rastorguev; Johann Gerein; Wolfgang Draf; Joachim Schirren Journal: Otolaryngol Head Neck Surg Date: 2005-03 Impact factor: 3.497
Authors: Michael Mohr; Christoph Schliemann; Christoph Biermann; Lars-Henning Schmidt; Torsten Kessler; Joachim Schmidt; Karsten Wiebe; Klaus-Michael Müller; Thomas K Hoffmann; Andreas H Groll; Claudius Werner; Christina Kessler; Rainer Wiewrodt; Claudia Rudack; Wolfgang E Berdel Journal: Oncol Lett Date: 2014-08-28 Impact factor: 2.967
Authors: Douglas R Sidell; Karthik Balakrishnan; Simon R Best; Karen Zur; Julia Buckingham; Alessandro De Alarcon; Fuad M Baroody; Jonathan M Bock; Emily F Boss; Charles M Bower; Paolo Campisi; Sharon F Chen; Jeffrey M Clarke; Kevin D Clarke; Alejandro Cocciaglia; Robin T Cotton; Giselle Cuestas; Kara L Davis; Victor H DeFago; Frederik G Dikkers; Ines Dossans; Walter Florez; Elizabeth Fox; Aaron D Friedman; Nazaneen Grant; Osama Hamdi; Norman D Hogikyan; Kaalan Johnson; Liane B Johnson; Romaine F Johnson; Peggy Kelly; Adam M Klein; Claire M Lawlor; Nicolas Leboulanger; Alejandro G Levy; Derek Lam; Greg R Licameli; Steve Long; David G Lott; Dayse Manrique; James Scott McMurray; Kara D Meister; Anna H Messner; Michael Mohr; Pamela Mudd; Anthony J Mortelliti; Daniel Novakovic; Julian Ongkasuwan; Shazia Peer; Krysztof Piersiala; Jeremy D Prager; Seth M Pransky; Diego Preciado; Tiffany Raynor; Rico N P M Rinkel; Hugo Rodriguez; Verónica P Rodríguez; John Russell; María Laura Scatolini; Patrick Scheffler; David F Smith; Lee P Smith; Marshall E Smith; Richard J H Smith; Abraham Sorom; Amalia Steinberg; John A Stith; Dana Thompson; Jerome W Thompson; Patricio Varela; David R White; Andre M Wineland; Christina J Yang; Carlton J Zdanski; Craig S Derkay Journal: Laryngoscope Date: 2021-01-06 Impact factor: 2.970
Authors: Cem Sievers; Yvette Robbins; Ke Bai; Xinping Yang; Paul E Clavijo; Jay Friedman; Andrew Sinkoe; Scott M Norberg; Christian Hinrichs; Carter Van Waes; Clint T Allen Journal: Commun Biol Date: 2021-12-20